Cargando…

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia

Detalles Bibliográficos
Autores principales:	Gavriatopoulou, Maria, Kastritis, Efstathios, Dimopoulos, Meletios Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849145/ https://www.ncbi.nlm.nih.gov/pubmed/29560081 http://dx.doi.org/10.18632/oncotarget.23400

Ejemplares similares

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

How I treat rituximab refractory patients with WM
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial
por: Trotman, Judith, et al.
Publicado: (2021)

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
por: Buske, Christian, et al.
Publicado: (2022)

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
por: Kersten, Marie José, et al.
Publicado: (2022)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Exercise-Induced Changes in Tumor Growth via Tumor Immunity
por: Spiliopoulou, Polyxeni, et al.
Publicado: (2021)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
por: Rosati, Margherita, et al.
Publicado: (2022)

Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants
por: Terpos, Evangelos, et al.
Publicado: (2022)

Deep Sternal Wound Tuberculosis with Hypo-gamma-globulinemia
por: Hamada, Kazuki, et al.
Publicado: (2018)

The extended 4-year follow-up results of the ELOQUENT-2 trial
por: Gavriatopoulou, Maria, et al.
Publicado: (2019)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
por: Büyükkurt, Nurhilal, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia
por: Fotiou, Despina, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
por: Dimopoulos, M. A., et al.
Publicado: (2016)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy
por: Aiello, Andrea, et al.
Publicado: (2017)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

Monoclonal Gammopathy of Thrombotic Significance
por: Gkalea, Vasiliki, et al.
Publicado: (2023)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia
por: Poza, María, et al.
Publicado: (2021)

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
por: Gustine, Joshua N., et al.
Publicado: (2021)

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA
por: Dimopoulos, M.-A., et al.
Publicado: (2022)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia
por: Wallace, Mark R.
Publicado: (2020)

Ventricular Tachycardia Storm in a Patient Treated With Ibrutinib for Waldenstrom Macroglobulinemia
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
por: Castillo, Jorge J., et al.
Publicado: (2022)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Zanwar, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttgqu5scqpmmg4t2jvkqlfn6du